The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. (Q38068293)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249839%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

S J Vandecasteele

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249839%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

E Tacconelli

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249839%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

18 December 2012

1 reference

Journal of Antimicrobial Chemotherapy

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249839%20AND%20SRC:MED&resulttype=core&format=json

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249839%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249839%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

743-748

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249839%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

4

1 reference

Clinical pharmacokinetics of vancomycin

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Epidemiology of staphylococcal resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Recent changes in vancomycin use in renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Preventing the influx of vancomycin-resistant enterococci into health care institutions, by use of a simple validated prediction rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Vancomycin ototoxicity: a reevaluation in an era of increasing doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

The pharmacokinetic and pharmacodynamic properties of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Vancomycin: we can't get there from here.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495

Meta-analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS495